5004592025-04-012025-06-305004592025-04-012025-06-30in-capmkt:OtherExpenses1Member5004592025-04-012025-06-30in-capmkt:OtherExpenses2Member5004592025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500459PGHHNOTLISTEDINE179A01014Procter & Gamble Hygiene and Health Care LimitedMain BoardEquity2025-04-012026-03-312025-07-30INRLakhsQuarterlyFirst quarterSingle segmentHygiene and Health Care2025-07-3012:44:002025-07-3013:15:00Not applicablefalsefalseNo default. 2025-04-012025-06-30UnauditedStandalone937030000076900000944720000016440000002024800000-257100000483500000700000909000002813400000680020000026470000000264700000071840000080000007264000000192060000000001920600000-1770000019029000003246000001059.1759.170059.1759.171. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 30th July, 2025 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <BR> 2. The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India. <BR> 3. The Board of Directors of the Company, on January 23, 2025, approved the change of the previous Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ended on March 31, 2025. <BR> 4.During the year ended June 30, 2024, certain Property, Plant & Equipment of the Company having a written down value of 2,282 lakhs were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, had been tested for impairment and an impairment loss amounting to 1,303 lakhs had been recognized in the financial results. During the nine months period ended March 31, 2025, the Company had re-assessed the impairment recognised based on an “Agreement to Sell” entered into with a buyer and had reversed the excess provision for impairment loss of 673 lakhs under “Other Income”. <BR> 4.The Company's operating segments under Ind AS 108 – Operating Segments are as follows: <BR> - Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets. <BR> - Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene. These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided. <BR> 6. The Company's operating segments under Ind AS 108 – Operating Segments are as follows: <BR> - Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets. <BR> - Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene. 5. These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided. <BR> 7. The figures for the preceeding three months ended March 31, 2025, are the balancing figures between the audited figures in respect of the nine month period ended March 31, 2025 and the published unaudited year to date figures upto the end of the second quarter ended December 31, 2024. <BR> 8. The figures for the preceeding three months ended March 31, 2025, are the balancing figures between the audited figures in respect of the nine month period ended March 31, 2025 and the published unaudited year to date figures upto the end of the second quarter ended December 31, 2024. <BR> <BR> Advertisement and sales promotion expense687300000Other Expenses2126100000Re-measurement of defined benefit plans-23600000-23600000-5900000-17700000